Clinical Trial Update: Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nilotinib for cytomegalovirus prophylaxis and treatment following allogeneic hematopoietic stem cell transplantation has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Hematopoietic Stem Cell Transplantation-related Complications
• Cytomegalovirus Infection

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Patients Who Have Received Allo-HSCT | Phase 2 | Status: COMPLETED